Invitae Co. (NYSE:NVTA) Receives $10.33 Average Price Target From Analysts
Invitae Co. (NYSE:NVTA) Receives $10.33 Average Price Target From Analysts
Shares of Invitae Co. (NYSE:NVTA – Get Rating) have been given an average recommendation of "Hold" by the thirteen ratings firms that are presently covering the company, Marketbeat Ratings reports. Four investment analysts have rated the stock with a sell rating and eight have assigned a hold rating to the company. The average 1 year price objective among brokerages that have updated their coverage on the stock in the last year is $8.45.
Invitae Co. 的股票Marketbeat Ratings报道，目前报道该公司的十三家评级公司对纽约证券交易所代码：NVTA — 获取评级）的平均推荐为 “持有”。四位投资分析师对该股进行了卖出评级，八位对该公司给予了持有评级。去年更新该股报道的经纪商的平均1年价格目标为8.45美元。
NVTA has been the subject of a number of research reports. StockNews.com raised shares of Invitae to a "sell" rating in a research note on Friday. SVB Leerink lifted their price objective on shares of Invitae from $2.50 to $3.00 and gave the company a "market perform" rating in a research note on Wednesday, November 9th. Cowen lowered shares of Invitae from an "outperform" rating to a "market perform" rating in a research note on Tuesday, July 26th. Credit Suisse Group initiated coverage on shares of Invitae in a research note on Wednesday, August 24th. They issued an "underperform" rating for the company. Finally, Cowen lifted their price objective on shares of Invitae to $2.80 in a research note on Tuesday, November 15th.
NVTA 一直是许多研究报告的主题。StockNews.com在周五的一份研究报告中将Invitae的股票评级提高至 “卖出”。SVB Leerink在11月9日星期三的一份研究报告中将Invitae股票的目标价格从2.50美元上调至3.00美元，并将该公司评为 “市场表现”。Cowen在7月26日星期二的一份研究报告中将Invitae的股票评级从 “跑赢大盘” 下调至 “市场表现”。瑞士信贷集团在8月24日星期三的一份研究报告中开始报道Invitae的股票。他们为该公司发布了 “表现不佳” 的评级。最后，Cowen在11月15日星期二的一份研究报告中将Invitae股票的目标价格上调至2.80美元。
Invitae Stock Performance
邀请股票表现
Invitae stock opened at $2.74 on Tuesday. The company has a 50 day moving average price of $2.63 and a 200 day moving average price of $2.95. Invitae has a 52 week low of $1.83 and a 52 week high of $18.87. The company has a quick ratio of 6.18, a current ratio of 6.44 and a debt-to-equity ratio of 10.03.
Invitae股票周二开盘价为2.74美元。该公司的50天移动平均线价格为2.63美元，200天移动平均线价格为2.95美元。Invitae创下52周低点1.83美元，52周高点为18.87美元。该公司的速动比率为6.18，流动比率为6.44，债务与权益比率为10.03。
Institutional Inflows and Outflows
机构流入和流出
Institutional investors and hedge funds have recently made changes to their positions in the stock. Financial Advocates Investment Management bought a new position in shares of Invitae during the 3rd quarter worth about $206,000. Operose Advisors LLC bought a new stake in Invitae in the first quarter valued at about $32,000. AdvisorNet Financial Inc increased its stake in Invitae by 61.0% in the third quarter. AdvisorNet Financial Inc now owns 10,000 shares of the medical research company's stock valued at $25,000 after acquiring an additional 3,788 shares during the period. Credit Agricole S A bought a new stake in Invitae in the third quarter valued at about $25,000. Finally, Clearwater Capital Advisors LLC bought a new stake in Invitae in the first quarter valued at about $82,000. Institutional investors own 88.27% of the company's stock.
机构投资者和对冲基金最近改变了他们在股票中的头寸。金融倡导者投资管理公司在第三季度购买了价值约20.6万美元的Invitae股票新头寸。Operose Advisors LLC在第一季度收购了Invitae的新股份，价值约32,000美元。AdvisorNet Financial Inc在第三季度将其在Invitae的股份增加了61.0％。AdvisorNet Financial Inc在此期间又收购了3,788股股票后，现在拥有这家医学研究公司的10,000股股票，价值25,000美元。法国农业信贷银行股份有限公司在第三季度收购了Invitae的新股份，价值约为25,000美元。最后，Clearwater Capital Advisors LLC在第一季度收购了Invitae的新股份，价值约为82,000美元。机构投资者拥有该公司88.27％的股票。
About Invitae
关于 Invitae
(Get Rating)
（获取评分）
Invitae Corporation, a medical genetics company, integrates genetic information into mainstream medicine to improve healthcare of people in the United States, Canada, and internationally. The company offers genetic tests in various clinical areas, including hereditary cancer, cardiology, neurology, pediatrics, oncology, metabolic conditions, and rare diseases; digital health solutions; and health data services.
Invitae Corporation是一家医学遗传学公司，将遗传信息整合到主流医学中，以改善美国、加拿大和国际上人们的医疗保健。该公司提供各种临床领域的基因检测，包括遗传性癌症、心脏病学、神经病学、儿科、肿瘤学、代谢病和罕见疾病；数字健康解决方案；以及健康数据服务。
Further Reading
进一步阅读
- Get a free copy of the StockNews.com research report on Invitae (NVTA)
- Three Ways To Win The Online Gambling Industry
- Santa Claus Rally? Here's What Needs to Happen
- Will the Return of Bob Iger Return the Magic to Disney Stock?
- Is Ardelyx is A Buy After Slip in Early 2022
- Is Tesla A Bargain Now As It Trades At Two-Year Lows?
- 免费获取 StockNews.com 关于 Invitae (NVTA) 的研究报告的副本
- 赢得在线赌博业的三种方法
- 圣诞老人拉力赛？这是需要发生的事情
- 鲍勃·艾格的回归会将魔法带回迪士尼股票吗？
- Ardelyx 是 2022 年初一次又一次的下跌吗
- 特斯拉现在是便宜货吗，因为它的交易价格处于两年低点？
Receive News & Ratings for Invitae Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invitae and related companies with MarketBeat.com's FREE daily email newsletter.
每天接收 Invitae 的新闻和评级 -在下面输入您的电子邮件地址，即可通过Marketbeat.com的免费每日电子邮件时事通讯接收Invitae及相关公司的最新新闻和分析师评级的简明每日摘要。
译文内容由第三方软件翻译。